Renvela Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
This article reviews the key results from these observational studies of sucroferric oxyhydroxide and evaluates its role in the management of hyperphosphatemia in clinical practice.PMID:35138627 | DOI:10.1007/s40620-021-01241-5 (Source: Journal of Nephrology)
Source: Journal of Nephrology - February 9, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Stuart M Sprague Marc Vervloet Rosa Ramos Kamyar Kalantar-Zadeh Source Type: research

Gut Microbiome-Derived Uremic Toxin Levels in Hemodialysis Patients on Different Phosphate Binder Therapies
Conclusion: There was no difference in the gut microbiome-derived UTOX levels between phosphate binders (SFO vs. SEV), despite SFO therapy resulting in fewer constipated participants. This pilot study may inform study design of future clinical trials and highlights the importance of including factors beyond bowel habits and their association with UTOX levels.Blood Purif (Source: Blood Purification)
Source: Blood Purification - August 10, 2021 Category: Hematology Source Type: research

Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality
Background: Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney disease (CKD) on dialysis. Mortality rates are still unacceptably high even though they have fallen in the past 2 decades. Hyperphosphatemia (elevated serum phosphate levels) is seen in almost all patients with advanced CKD and is by far the largest remaining modifiable contributor to CKD mortality.Summary: Phosphate retention drives multiple physiological mechanisms linked to increased risk of CVD. Fibroblast growth factor 23 and parathyroid hormone (PTH) levels, both of which have been suggested to have direct pathogenic CV...
Source: Cardiorenal Medicine - June 11, 2021 Category: Urology & Nephrology Source Type: research

Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-Separated Administration in Healthy Individuals
This study in healthy individuals investigated the effect of 2 PBs, sevelamer carbonate and calcium acetate, on the pharmacokinetic properties of a single oral dose of roxadustat administered concomitantly or with a time lag.METHODS: This 2-part, Phase I study was conducted with an open-label, randomized, 3-way (part 1) or 5-way (part 2) crossover design, with 5-day treatment periods. On day 1 of each period, participants received 200 mg roxadustat administered alone or (1) concomitantly with sevelamer carbonate (2400 mg) or calcium acetate (1900 mg) (part 1) or (2) 1 hour before or 1, 2, or 3 hours after sevelamer carbona...
Source: Clinical Therapeutics - May 8, 2021 Category: Drugs & Pharmacology Authors: Dorien Groenendaal-van de Meent Virginie Kerbusch Begona Barroso-Fernandez Martin den Adel Jan van Dijk Georg Golor Marloes Schaddelee Source Type: research

Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
Abstract The majority of patients with chronic kidney disease (CKD) receiving dialysis do not reach target serum phosphorus concentrations, despite treatment with phosphate binders. Tenapanor is a non-binder, sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor that reduces paracellular intestinal phosphate absorption. This pre-clinical study evaluated the effect of tenapanor and varying doses of sevelamer carbonate on urinary phosphorus excretion, a direct reflection of intestinal phosphate absorption. We measured 24-hour urinary phosphorus excretion in male rats assigned to groups dosed orally with vehic...
Source: American Journal of Physiology. Renal Physiology - December 7, 2020 Category: Physiology Authors: King AJ, Kohler J, Fung C, Jiang Z, Quach A, Kumaraswamy P, Chertow GM, Rosenbaum DP Tags: Am J Physiol Renal Physiol Source Type: research

Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study
Conclusion: This analysis indicates that sP control may be more challenging in younger patients with high sP levels. Closer monitoring and management of serum phosphorus levels may be required in this population.Nephron (Source: Nephron)
Source: Nephron - June 25, 2020 Category: Urology & Nephrology Source Type: research

Effect of calcitriol combined with sevelamer carbonate on serum parathyroid hormone in patients with chronic renal failure.
This study aimed to observe and analyze the effect of calcitriol combined with sevelamer carbonate on serum parathyroid hormone in patients with chronic renal failure. This study included 180 patients who had been treated for chronic renal failure in our hospital were enrolled as research objects. The patients were randomly divided into two groups: a research group and a control group, each containing 90 cases. The research group was treated with calcitriol combined with sevelamer carbonate, and the control group was treated with calcitriol alone. The therapeutic effects of the two groups were observed and analyzed by SPS...
Source: Cellular and Molecular Biology - May 18, 2020 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial
Conclusions3-month sevelamer treatment did not reduce proteinuria in patients with CKD on maximal RAS blockade. Amelioration of inflammation and dyslipidemia with sevelamer treatment raises the possibility that it may confer benefit in patients with CKD beyond reduction of proteinuria.FundingSanofi (Milan, Italy).Trial RegistrationRegistered at ClinicalTrials.gov with study number NCT01968759. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - June 20, 2019 Category: Urology & Nephrology Source Type: research

Phosphate binders, appetite and nutritional status in maintenance hemodialysis patients.
CONCLUSIONS: Regular use of these phosphate binders was not associated with anorexia, decreased dietary intake and nutritional status in the study population. Therefore, there is no preference in the choice of phosphate binders in MHD patients with hyperphosphatemia, even those who are at nutritional risk. PMID: 30485918 [PubMed - in process] (Source: Asia Pacific Journal of Clinical Nutrition)
Source: Asia Pacific Journal of Clinical Nutrition - December 3, 2018 Category: Nutrition Authors: Beberashvili I, Baskin O, Azar A, Katkov A, Feldman L, Gorelik O, Stav K, Efrati S Tags: Asia Pac J Clin Nutr Source Type: research

In-vitro Equilibrium Phosphate Binding Study of Sevelamer Carbonate by UV-Vis Spectrophotometry
Drug Res (Stuttg) DOI: 10.1055/a-0635-8246Sevelamer carbonate is a cross-linked polymeric amine; it is the active ingredient in Renvela® tablets. US FDA provides recommendation for demonstrating bioequivalence for the development of a generic product of sevelamer carbonte using in-vitro equilibrium binding study. A simple UV-vis spectrophotometry method was developed and validated for quantification of free phosphate to determine the binding parameter constant of sevelamer. The method validation demonstrated the specificity, limit of quantification, accuracy and precision of measurements. The validated method has been suc...
Source: Drug Research - June 12, 2018 Category: Drugs & Pharmacology Authors: Prasaja, Budi Syabani, M. Maulana Sari, Endah Chilmi, Uci Cahyaningsih, Prawitasari Kosasih, Theresia Weliana Tags: Original Article Source Type: research

Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study
Abstract IntroductionHyperphosphatemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients does not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate concentration on phosphate binding. . This interaction could be of relevance in clinical practice. MethodsPhosphate binding was quantified in vitro in 25 ml of purified water containing phosphate concentrations of 10, 15 and 20 mM and baseline pH values of 3.0 or 6.0, with a binder over 6 hours. Lanthanum carbonate, calcium acetate...
Source: Nephrology - February 26, 2018 Category: Urology & Nephrology Authors: Stefan P Schumacher, LJ Schurgers, G Vervloet Marc, Aegida Neradova Tags: Original Article Source Type: research